Claims for Patent: 4,997,915

Summary for Patent: 4,997,915

Title:	Purification of pertussis toxins
Abstract:	Lymphocytosis promoting factor (LPF) and filamentous hemaglutinin (FHA) are isolated from the growth medium of the Bordatella pertussis organism and purified by selecting adsorbing the LPF and FHA on a selective adsorbing medium, such as filter aids or gel filtration media, at low ionic strength and subsequently removing the adsorbed LPF and FHA at using an aqueous medium of high ionic strength, either simultaneously or sequentially. Prior to desorbtion of the LPF and FHA, the adsorbing medium may be contacted with an aqueous solution of a non-ionic detergent, which enables the LPF and FHA subsequently desorbed to be substantially free from contamination by lipopolysaccharides (LPS). The LPF and FHA may be further purified on hydroxyapatite. The LPF and FHA may be detoxified separately or together by contacting with a cross-linking agent, such as glutaraldehyde or formaldehyde, in the presence of an anti-aggregation agent. The resulting purified and detoxified LPF and FHA may be used to formulate a vaccine against pertussis.
Inventor(s):	Larry U. L. Tan, Dirk Alkema, Gail Jackson, Po S. Wah
Assignee:	Sanofi Pasteur Ltd
Application Number:	US07/333,964

Details for Patent 4,997,915

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Sanofi Pasteur Limited	QUADRACEL	diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine	Injection	125525	March 24, 2015		2009-04-06